Viatris Stock News

PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" an...

Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data shows a clinically meaningful improvement in disease activity consistent with results from other global Phase 2 studies of cenerimod PITTSBURGH , Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTR...

The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.

Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive op...

Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.

Viatris Inc. (NASDAQ:VTRS ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Chief Executive Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Doretta Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Ekaterina Knyazkova - JPMorgan David Am...

Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.

PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% t...